English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Chronic Myeloid Leukaemia (CML) is a blood-derived proliferative disorder,which is highly associated to a translocation of chromosomes 9 and 22 or thecreation of Philadelphia chromosome Ph(+) cases, inducing the synthesis of achimeric fusion protein, namely BCR-ABL1 (Breakpoint Cluster Region-Abelson 1chimeric protein), which is known for driving the pathophysiology of thedisease, however variants of CML are also recognized as CML Ph(-), thesenonetheless account for a small percentage of the overall CML patients; posingthus the question whether BCR-ABL1 fusion protein is required for the whole ofthe pathophysiology of CML. Hereof, through a stochastic description, adiscrete time discrete Markov chain depicts the various protein-proteininteractions of BCR-ABL1 to better understand signalling pathways andtime-dependent evolution of these pathways, as well as to provide prospectivetherapeutic protein targets to improve both the specificity of the treatmentand the life-expectancy of the patients.

Novel therapeutic targets in chronic myeloid leukaemia through a discrete time discrete Markov chain model of BCR-ABL1 interactions